» Articles » PMID: 19092437

Clinical Practice and Genetic Counseling for Cystic Fibrosis and CFTR-related Disorders

Overview
Journal Genet Med
Publisher Elsevier
Specialty Genetics
Date 2008 Dec 19
PMID 19092437
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

Cystic fibrosis transmembrane conductance regulator-related disorders encompass a disease spectrum from focal male reproductive tract involvement in congenital absence of the vas deferens to multiorgan involvement in classic cystic fibrosis. The reproductive, gastrointestinal, and exocrine manifestations of cystic fibrosis transmembrane conductance regulator deficiency are correlated with CFTR genotype, whereas the respiratory manifestations that are the main cause of morbidity and mortality in cystic fibrosis are less predictable. Molecular genetic testing of CFTR has led to new diagnostic strategies and will enable targeting of molecular therapies now in development. Older diagnostic methods that measure sweat chloride and nasal potential difference nonetheless remain important because of their sensitivity and specificity. In addition, the measurement of immunoreactive trypsinogen and the genotyping of CFTR alleles are key to newborn screening programs because of low cost. The multiorgan nature of cystic fibrosis leads to a heavy burden of care, thus therapeutic regimens are tailored to the specific manifestations present in each patient. The variability of cystic fibrosis lung disease and the variable expressivity of mild CFTR alleles complicate genetic counseling for this autosomal recessive disorder. Widespread implementation of newborn screening programs among populations with significant cystic fibrosis mutation carrier frequencies is expected to result in increasing demands on genetic counseling resources.

Citing Articles

Connecting the Past and Present: An Updated Literature Review of Aquagenic Syringeal Acrokeratoderma.

Lindsay J, Incristi A, Liu A, Arnett B, Costa M, Chong C Cureus. 2025; 16(12):e76002.

PMID: 39835050 PMC: 11743320. DOI: 10.7759/cureus.76002.


Lung function improvement on triple modulators: high-resolution, nationwide data from the Danish Cystic Fibrosis Cohort.

Leo-Hansen C, Faurholt-Jepsen D, Qvist T, Hojte C, Nielsen B, Bryrup T ERJ Open Res. 2024; 10(6).

PMID: 39655171 PMC: 11626609. DOI: 10.1183/23120541.00339-2024.


Exploring Therapeutic Strategies for Pediatric Cystic Fibrosis: An In-Depth Comparative Review.

Lakhani A, Clementina R, Siddiqua Z, Shroff S, Bhavanam S, Pandya M Cureus. 2024; 16(10):e71913.

PMID: 39564025 PMC: 11576056. DOI: 10.7759/cureus.71913.


Clinical Course of a Child With Cystic Fibrosis and the Genotype F508del/CFTRdup1_11: A Case Report.

Petrocheilou A, Tzetis M, Loukou I Cureus. 2024; 16(8):e67792.

PMID: 39323708 PMC: 11423182. DOI: 10.7759/cureus.67792.


Optimization of the fluorogen-activating protein tag for quantitative protein trafficking and colocalization studies in .

Oppenheimer K, Hager N, McAtee C, Filiztekin E, Shang C, Warnick J Mol Biol Cell. 2024; 35(7):mr5.

PMID: 38809589 PMC: 11244157. DOI: 10.1091/mbc.E24-04-0174.


References
1.
Kiesewetter S, Macek Jr M, Davis C, Curristin S, Chu C, Graham C . A mutation in CFTR produces different phenotypes depending on chromosomal background. Nat Genet. 1993; 5(3):274-8. DOI: 10.1038/ng1193-274. View

2.
Girodon-Boulandet E, Cazeneuve C, Goossens M . Screening practices for mutations in the CFTR gene ABCC7. Hum Mutat. 2000; 15(2):135-49. DOI: 10.1002/(SICI)1098-1004(200002)15:2<135::AID-HUMU2>3.0.CO;2-H. View

3.
Gibson R, Emerson J, McNamara S, Burns J, Rosenfeld M, Yunker A . Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med. 2002; 167(6):841-9. DOI: 10.1164/rccm.200208-855OC. View

4.
Richards C, Bradley L, Amos J, Allitto B, Grody W, Maddalena A . Standards and guidelines for CFTR mutation testing. Genet Med. 2002; 4(5):379-91. DOI: 10.1097/00125817-200209000-00010. View

5.
de Jong P, Nakano Y, Lequin M, Mayo J, Woods R, Pare P . Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis. Eur Respir J. 2004; 23(1):93-7. DOI: 10.1183/09031936.03.00006603. View